Quantitative PCR analysis for Bcl-2/IgH in a phase III study of yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages 6094-6100

  Goff, Lindsey ^a   Summers, Karin ^a   Iqbal, Sameena ^a   Kuhlmann, Jens ^a   Kunz, Michael ^a   Louton, Tom ^a   Hagenbeek, Anton ^a   Morschhauser, Franck ^a   Putz, Barbara ^a   Lister, Andrew ^a   Rohatiner, Ama ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY; YTTRIUM;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; ADJUVANT THERAPY; DISEASE FREE SURVIVAL; GENE ORDER; GENETICS; MIDDLE AGED; PATHOLOGY; PROTO ONCOGENE; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; GENE ORDER; GENES, BCL-2; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 74949110327     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.6258     Document Type: Article

References (38)

1. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
2. Rohatiner AZ, Lister TA: The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 18:1-10, 2005
3. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
4. Anderson T, DeVita VT Jr, Simon RM, et al: Malignant lymphoma: II Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 50:2708-2721, 1982
5. Brittinger G, Bartels H, Common H, et al: Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 2:269-306, 1984
6. Liu Q, Fayad L, Cabanillas F, et al: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M. D. Anderson Cancer Center. J Clin Oncol 24:1582-1589, 2006
7. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23: 8447-8452, 2005
8. van Oers MH: Rituximab maintenance therapy: A step forward in follicular lymphoma. Haematologica 92:826-833, 2007
9. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005
10. Yunis JJ, Frizzera G, Oken MM, et al: Multiple recurrent genomic defects in follicular lymphoma: A possible model for cancer. N Engl J Med 316:79-84, 1987
11. Tilly H, Rossi A, Stamatoullas A, et al: Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84:1043-1049, 1994
12. Horsman DE, Connors JM, Pantzar T, et al: Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 30:375-382, 2001
13. Tsujimoto Y, Cossman J, Jaffe E, et al: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443, 1985
14. Graninger WB, Seto M, Boutain B, et al: Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 80:1512-1515, 1987
15. Hockenbery DM, Zutter M, Hickey W, et al: BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 88:6961-6965, 1991
16. Summers KE, Goff LK, Wilson AG, et al: Frequency of the Bcl-2/IgH rearrangement in normal individuals: Implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol 19:420-424, 2001
17. Cleary ML, Sklar J: Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 82:7439-7443, 1985
18. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 83:5214-5218, 1986
19. Dolken G, Illerhaus G, Hirt C, et al: BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 14:1333-1344, 1996
20. Summers KE, Davies AJ, Matthews J, et al: The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction. Br J Haematol 118:563-566, 2002
21. Morschhauser F, Radford J, Van HA, et al: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
22. Wiseman GA, Gordon LI, Multani PS, et al: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 99:4336-4342, 2002
23. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21: 1263-1270, 2003
24. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
25. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463, 2002
26. Ansell SM, Ristow KM, Habermann TM, et al: Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20:3885-3890, 2002
27. Dolken L, Schuler F, Dolken G: Quantitative detection of t(14;18)-positive cells by real-time quantitative PCR using fluorogenic probes. Biotechniques 25:1058-1064, 1998
28. Rambaldi A, Carlotti E, Oldani E, et al: Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and longterm outcome in follicular non-Hodgkin lymphoma. Blood 105:3428-3433, 2005
29. Montoto S, Moreno C, Domingo-Domenech E, et al: High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica 93:207-214, 2008
30. Crawley CR, Foran JM, Gupta RK, et al: A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann Oncol 11:861-865, 2000
31. Rambaldi A, Lazzari M, Manzoni C, et al: Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 99:856-862, 2002
32. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al: The clinical significance of molecular response in indolent follicular lymphomas. Blood 91: 2955-2960, 1998
33. Lopez-Guillermo A, Cabanillas F, McDonnell TI, et al: Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 93:3081-3087, 1999
34. Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999
35. Ladetto M, Corradini P, Vallet S, et al: High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: A multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100:1559-1565, 2002
36. Bishton MJ, Hicks RJ, Westerman DA, et al: A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy. Haematologica 93:789-790, 2008
37. Kaminski MS, Tuck M, Estes J, et al: 131Itositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005
38. Illidge TM, Bayne M, Brown NS, et al: Phase 1/2 study of fractionated (131)I-rituximab in lowgrade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113:1412-1421, 2009